|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
 |
Download final outline programme View conference abstracts  |
|
Toshiyuki Yoneda (San Antonio, USA) Cancer and bone Topics to be covered The topic to be discussed is whether bone can be a harbour for
breast cancer cells to spread to visceral organs. Recently it is
reported the bisphosphonate zoledronic acid (ZOL) combined with
hormone therapy significantly prolonged survival of breast cancer
patients compared with hormone therapy alone. Since bone metastases
per se are not life-threatening, these results suggest ZOL suppressed
metastases to visceral organs and are consistent with the notion
that ZOL has anti-cancer actions. Moreover, previous experimental
studies reported that ZOL inhibited not only bone metastases but
also lung and liver metastases of breast cancer in an orthotopic
animal model of metastasis, again suggesting anti-cancer effects
of ZOL. Of note, however, ZOL failed to inhibit breast tumour development
at the mammary fat pad, suggesting inhibition of visceral metastases
is not due to direct anti-cancer effects of ZOL. Rather, inhibition
of bone metastases by ZOL may modulate subsequent metastases to
visceral organs. I would like to discuss how clinically and experimentally
we will be able to prove this notion. If this turns out to be the
case, suppression of bone by BP would be primary strategy of treatment
of metastasis. Educational goals After attending this Meet the Professor session, participants will be expected to:
Target audience Young researchers who are interested in cancer stem cells and metastatic niche in bone marrow. Teaching methods I will start the session by illustrating my hypothesis by hand-writing
and call discussion from the audience. |
 |
 |
|
 |
|
|
|
|